Region ratios of ‘treatment effect’ in Japan+Korea and Not-Japan+Korea patients, where ‘treatment effect’ is the comparison between treatment arms of 24h urinary cortisol excretion ratio (end of treatment/baseline; Urinary Cortisol population). (DOCX 944 KB
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...
Algorithm used to calculate current and past use in the cohort analysis. Schematic description of th...
Effects of Dexamethasone, PIK-294 and tofacinib on IL-6 from TCR-stimulated BAL cells. BAL cells fro...
AEs reported by âĽ3 patients in the Japan+Korea cohort of any relevant treatment arm and the corres...
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
Summary of the most common adverse events (âĽ5%) in the Asian and non-Asian populations. (DOCX 24 k...
Asthma quality of life questionnaire score (pooled data) in Asian and non-Asian patients, at baselin...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Flowchart of the study population. Detailed information on characteristics and co-medication of case...
Supplementary appendix: The anti-inflammatory duration of action of fluticasone furoate/vilanterol t...
Additional results for patient demographics and baseline characteristics, exacerbation rates, exacer...
Table S1. Post hoc analysis of SIRIUS (demographics and clinical characteristics). (DOC 45 kb
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...
Algorithm used to calculate current and past use in the cohort analysis. Schematic description of th...
Effects of Dexamethasone, PIK-294 and tofacinib on IL-6 from TCR-stimulated BAL cells. BAL cells fro...
AEs reported by âĽ3 patients in the Japan+Korea cohort of any relevant treatment arm and the corres...
Adjusted treatment differences from baseline in trough FEV1 at Week 12 (Efficacy population). (DOCX ...
Profile of the three Phase III studies included in both the efficacy and safety analyses. (DOCX 47.4...
Profile of the two additional Phase IIb studies included in only the safety analyses. (DOCX 25.6 KB
List of Institutions and Independent Ethics Committees/Institutional Review Boards for Studies HZA10...
Summary of the most common adverse events (âĽ5%) in the Asian and non-Asian populations. (DOCX 24 k...
Asthma quality of life questionnaire score (pooled data) in Asian and non-Asian patients, at baselin...
e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results...
Flowchart of the study population. Detailed information on characteristics and co-medication of case...
Supplementary appendix: The anti-inflammatory duration of action of fluticasone furoate/vilanterol t...
Additional results for patient demographics and baseline characteristics, exacerbation rates, exacer...
Table S1. Post hoc analysis of SIRIUS (demographics and clinical characteristics). (DOC 45 kb
Scatter plot of ACQ and miniAQLQ scores. Table S1. Characteristics of asthma. Table S2. Lung functio...
Algorithm used to calculate current and past use in the cohort analysis. Schematic description of th...
Effects of Dexamethasone, PIK-294 and tofacinib on IL-6 from TCR-stimulated BAL cells. BAL cells fro...